PEPeter J. van Den Elsen

Peter J. van Den Elsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter J. van Den Elsen has a total of 322 co-authors. Here are the top co-authors by number of shared publications:

  • Marja C.J.A. van Eggermond

    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands

    9 shared publications
  • Nienke van der Stoep

    Division of Molecular Biology, Department of Immunohematology and Blood Transfusion, Building 1, E3-Q, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands

    9 shared publications
  • Hedwich F. Kuipers

    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands

    7 shared publications
  • Rutger J. Wierda

    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands

    7 shared publications
  • Jaak M. Vossen

    Departments of Pediatrics (B.G., M.T., J.V.), Leiden, The Netherlands

    6 shared publications
  • Tjadine M. Holling

    6 shared publications

Latest Publications

  • A role for KMT1c in monocyte to dendritic cell differentiation

    by Rutger J. Wierda, Marieke Goedhart, Marja C.J.A. van Eggermond, Alice F. Muggen, Xanne M. Miggelbrink, Sacha B. Geutskens, Erik van Zwet, Geert W. Haasnoot, Peter J. van Den Elsen


  • Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques

    by Rutger J. Wierda, Inge M. Rietveld, Marja C.J.A. van Eggermond, Jeroen A.M. Belien, Erik W. van Zwet, Jan H.N. Lindeman, Peter J. van Den Elsen


  • Skewed Expression of the Genes Encoding Epigenetic Modifiers in High-Risk Uveal Melanoma

    by Naoimh Herlihy, Mehmet Dogrusöz, T. Huibertus van Essen, J. William Harbour, Pieter A. van der Velden, Marja C. J. A. van Eggermond, Geert W. Haasnoot, Peter J. van Den Elsen, Martine J. Jager

    Purpose. Monosomy 3 (M3) or the presence of a specific RNA expression profile, known as class 2, is strongly associated with death from uveal melanoma (UM). Given the important role of epigenetic processes in cancer development and progression, we compared the transcriptional profiles of a selection of epigenetic regulators between primary UM with a good and a bad prognosis. Methods. Transcriptional levels of 59 epigenetic regulator genes were measured by quantitative PCR (qPCR) in 20 UM, 12 with monosomy of chromosome 3 (M3) and 8 with disomy of chromosome 3 (D3). Validation was performed in an independent cohort. Expression levels were compared to clinicopathological characteristics, including class type. Bisulfite sequencing was used to evaluate the role of DNA methylation in gene silencing. Results. In the first set of tumors, general downregulation of transcription of the genes encoding epigenetic regulatory enzymes was seen in association with M3. The 10 genes with the highest differential expression between M3 and D3 were selected and were analyzed in a second set of tumors. In the validation set, significantly lower levels of KAT2B (P = 0.008), HDAC11 (P = 0.009), KMT1C (P = 0.05), KDM4B (P = 0.003), KDM6B (P = 0.04), and BMI-1 (P = 0.001) transcripts were found in tumors with M3/class 2. Methylation of C-phosphate-G (CpG) residues was not observed on the putative regulatory regions of KAT2B, KDM4B, or KDM6B. Conclusions. Expression levels of a number of histone-modifying genes and polycomb family members are significantly lower in uveal melanoma with monosomy 3/class 2, supporting a general dysregulation of epigenetic modifiers in UM with a bad prognosis.


  • T Cell Factor 1 Represses CD8+ Effector T Cell Formation and Function

    by Machteld M Tiemessen, Miranda R M Baert, Lianne Kok, Marja C J A van Eggermond, Peter J van Den Elsen, Ramon Arens, Frank J T Staal

    The Wnt-responsive transcription factor T cell factor 1 (Tcf1) is well known for its role in thymic T cell development and the formation of memory CD8+ T cells. However, its role in the initial phases of CD8+ T effector cell formation has remained unexplored. We report that high levels of Wnt signaling and Tcf1 are operational in naive and memory CD8+ T cells, whereas Wnt signaling and Tcf1 were low in effector CD8+ T cells. CD8+ T cells deficient in Tcf1 produce IFN-γ more rapidly, coinciding with increased demethylation of the IFN-γ enhancer and higher expression of the transcription factors Tbet and Blimp1. Moreover, virus-specific Tcf1−/− CD8+ T cells show accelerated expansion in acute infection, which is associated with increased IFN-γ and TNF production and lower viral load. Genetic complementation experiments with various Tcf1 isoforms indicate that Tcf1 dosage and protein stability are critical in suppressing IFN-γ production. Isoforms lacking the β-catenin binding domain are equally effective in inhibiting CD8+ effector T cell formation. Thus, Tcf1 functions as a repressor of CD8+ effector T cell formation in a β-catenin/Wnt-independent manner.


  • Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines

    by Anne Benard, Connie M. Janssen, Peter J. van Den Elsen, Marja C. J. A. van Eggermond, Dave S. B. Hoon, Cornelis J. H. van de Velde, Peter J. K. Kuppen

    The apoptosis pathway of programmed cell death is frequently deregulated in cancer. An intact apoptosis pathway is required for proper response to anti-cancer treatment. We investigated the chromatin status of key apoptosis genes in the apoptosis pathway in colorectal cancer cell lines in relation to apoptosis induced by chemo-, immune- or radiation therapy. Using chromatin immunoprecipitation (ChIP), we measured the presence of transcription-activating histone modifications H3Ac and H3K4me3 and silencing modifications H3K9me3 and H3K27me3 at the gene promoter regions of key apoptosis genes Bax, Bcl2, Caspase-9, Fas (CD95) and p53. Cell lines DLD1, SW620, Colo320, Caco2, Lovo and HT29 were treated with cisplatin, anti-Fas or radiation. The apoptotic response was measured by flow cytometry using propidium iodide and annexin V-FITC. The chromatin status of the apoptosis genes reflected the activation status of the intrinsic (Bax, Bcl2, Caspase-9 and p53) and extrinsic (Fas) pathways. An active intrinsic apoptotic pathway corresponded to sensitivity to cisplatin and radiation treatment of cell lines DLD1, SW620 and Colo320. An active Fas promoter corresponded to an active extrinsic apoptotic pathway in cell line DLD1. mRNA expression data correlated with the chromatin status of the apoptosis genes as measured by ChIP. In conclusion, the results presented in this study indicate that the balance between activating and silencing histone modifications, reflecting the chromatin status of apoptosis genes, can be used to predict the response of tumor cells to different anti-cancer therapies and could provide a novel target to sensitize tumors to obtain adequate treatment responses.


  • The epigenetics of multiple sclerosis and other related disorders

    by Peter J. van Den Elsen, Marja C.J.A. van Eggermond, Fabiola Puentes, Paul van der Valk, David Baker, Sandra Amor


  • Simvastatin reduces CCL2 expression in monocyte-derived cells by induction of a repressive CCL2 chromatin state

    by Dalila L. Zanette, Marja C.J.A. van Eggermond, Geert Haasnoot, Peter J. van Den Elsen


  • Open Access

    Hantaviral mechanisms driving HLA class I antigen presentation require both RIG‐I and TRIF

    by Pritesh Lalwani, Martin J. Raftery, Lidija Kobak, Andreas Rang, Thomas Giese, Markus Matthaei, Peter J. van Den Elsen, Thorsten Wolff, Detlev H. Krüger, Günther Schönrich

    Hantaviruses are emerging human pathogens. They induce an unusually strong antiviral response of human HLA class I (HLA‐I) restricted CD8+ T cells that may contribute to tissue damage and hantavirus‐associated disease. In this study, we analyzed possible hantaviral mechanisms that enhance the HLA‐I antigen presentation machinery. Upon hantavirus infection of various human and primate cell lines, we observed transactivation of promoters controlling classical HLA molecules. Hantavirus‐induced HLA‐I upregulation required proteasomal activity and was associated with increased TAP expression. Intriguingly, human DCs acquired the capacity to cross‐present antigen upon hantavirus infection. Furthermore, knockdown of TIR domain containing adaptor inducing IFN‐β or retinoic acid inducible gene I abolished hantavirus‐driven HLA‐I induction. In contrast, MyD88‐dependent viral sensors were not involved in HLA‐I induction. Our results show that hantaviruses strongly boost the HLA‐I antigen presentation machinery by mechanisms that are dependent on both retinoic acid inducible gene I and TIR domain containing adaptor inducing IFN‐β.


  • Open Access

    Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects

    by Corry Mr Weemaes, Maarten Jd van Tol, Jun Wang, Monique M van Ostaijen-Ten Dam, Marja Cja van Eggermond, Peter E Thijssen, Caner Aytekin, Nicola Brunetti-Pierri, Mirjam van der Burg, E Graham Davies, et al.

    Immunodeficiency with centromeric instability and facial anomalies (ICF) syndrome is a primary immunodeficiency, predominantly characterized by agammaglobulinemia or hypoimmunoglobulinemia, centromere instability and facial anomalies. Mutations in two genes have been discovered to cause ICF syndrome: DNMT3B and ZBTB24. To characterize the clinical features of this syndrome, as well as genotype–phenotype correlations, we compared clinical and genetic data of 44 ICF patients. Of them, 23 had mutations in DNMT3B (ICF1), 13 patients had mutations in ZBTB24 (ICF2), whereas for 8 patients, the gene defect has not yet been identified (ICFX). While at first sight these patients share the same immunological, morphological and epigenetic hallmarks of the disease, systematic evaluation of all reported informative cases shows that: (1) the humoral immunodeficiency is generally more pronounced in ICF1 patients, (2) B- and T-cell compartments are both involved in ICF1 and ICF2, (3) ICF2 patients have a significantly higher incidence of intellectual disability and (4) congenital malformations can be observed in some ICF1 and ICF2 cases. It is expected that these observations on prevalence and clinical presentation will facilitate mutation-screening strategies and help in diagnostic counseling.


  • Open Access

    Genetic and Epigenetic Regulation of CCR5 Transcription

    by Rutger J. Wierda, Peter J. Van Den Elsen

    The chemokine receptor CCR5 regulates trafficking of immune cells of the lymphoid and the myeloid lineage (such as monocytes, macrophages and immature dendritic cells) and microglia. Because of this, there is an increasing recognition of the important role of CCR5 in the pathology of (neuro-) inflammatory diseases such as atherosclerosis and multiple sclerosis. Expression of CCR5 is under the control of a complexly organized promoter region upstream of the gene. The transcription factor cAMP-responsive element binding protein 1 (CREB-1) transactivates the CCR5 P1 promoter. The cell-specific expression of CCR5 however is realized by using various epigenetic marks providing a multivalent chromatin state particularly in monocytes. Here we discuss the transcriptional regulation of CCR5 with a focus on the epigenetic peculiarities of CCR5 transcription.